- ►adisonline.com [PDF] M Rendell - Drugs, 2004 - ingentaconnect.com The sulphonylureas act by triggering insulin release from the pancreatic β cell. Abstract A specific
site on the adenosine triphosphate (ATP)-sensitive potassium channels is occupied by sulphonylureas
leading to closure of the potassium channels and subsequent opening of calcium ... Cited by 87 - Related articles - BL Direct - All 7 versions
EN Liberopoulos, DP Mikhailidis, MS Elisaf - Obesity Reviews, 2005 - interscience.wiley.com The metabolic syndrome is a constellation of interrelated abnormalities that increase the risk
for cardiovascular disease and progression to type 2 diabetes. The prevalence of this syndrome
is increasing because of the 'obesity epidemic'. The National Cholesterol Education ... Cited by 60 - Related articles - BL Direct - All 7 versions
P Home - Current Medical Research and Opinion®, 2005 - informahealthcare.com University of Newcastle upon Tyne, Newcastle upon Tyne, UK ... Address for
correspondence: Professor Philip Home, School of Clinical Medical Sciences – Diabetes, The
Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. Tel: +44 191 ... Cited by 51 - Related articles - All 6 versions
EN Liberopoulos, S Tsouli, DP Mikhailidis, MS … - Current Drug …, 2006 - ingentaconnect.com 1Department of Clinical Biochemistry (Vascular Disease Prevention clinics), Royal Free Hospital
University College School of Medicine (University of London), London, UK and 2Department
of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece Cited by 48 - Related articles - BL Direct - All 2 versions
- ►diabetesjournals.org J Gerich, P Raskin, L Jean-Louis, D Purkayastha, … - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—We conducted a randomized, multicenter,
double-masked, 2-year study of 428 drug-naïve patients with type 2 diabetes. Patients received
120 mg ac nateglinide or 1.25 mg qd glyburide plus 500 mg qd open-label metformin for ... Cited by 44 - Related articles - BL Direct - All 10 versions
- ►diabetesjournals.org V Fonseca, G Grunberger, S Gupta, S Shen, JE … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—In placebo-treated patients, HbA 1c did not change (Δ = 0.0 ± 0.1%). In patients
randomized to nateglinide, HbA 1c decreased from 8.3 to 7.5% (Δ = −0.8 ± 0.1%, P < 0.0001
vs. placebo). Target HbA 1c (<7.0%) was achieved by 38% of patients treated with ... Cited by 36 - Related articles - BL Direct - All 9 versions
- ►jabfm.com J Curtis, C Wilson - Journal of the American Board of Family …, 2005 - Am Board Family Med Type 2 diabetes is a serious, costly, and increasingly common disease. Several conditions commonly
seen in family medicine settings confer increased risk of developing diabetes. Among these conditions
are impaired glucose tolerance, impaired fasting glucose, obesity, gestational diabetes, ... Cited by 25 - Related articles - All 11 versions
D Prabhakaran, SS Anand - Vascular Medicine, 2004 - vmj.sagepub.com Abstract: The common clustering of glucose intolerance, insulin resistance, abdominal
adipos- ity, elevated blood pressure, and low HDL cholesterol is referred to as metabolic
syndrome. Indi- viduals with this syndrome have an increased risk of developing ... Cited by 20 - Related articles - BL Direct - All 3 versions
SI McFarlane, JJ Shin, T Rundek, JT Bigger - Current Diabetes Reports, 2003 - Springer Introduction The rising prevalence and increasing incidence of type 2 diabetes are alarming
in the United States and worldwide. It is estimated that by the year 2025 there will be over 300
million people diagnosed with diabetes around the world [1]. In the United States, as the ... Cited by 18 - Related articles - BL Direct - All 2 versions
